Amgen was aiming to launch its cholesterol-fighter Repatha quickly in India. But a panel of CV and renal specialists blocked the PCSK9 drug instead.

Chinese-American diagnostics specialist says it is building a new La Jolla lab to support U.S. product launches.

Approving the inadequately tested drug, simply because it is cheap, is "incomprehensible," says expert.

By selling its Wako chemicals unit, the top Japanese drugmaker Takeda could raise $1 billion for reinvestment in its pipeline.

The FDA has read the riot act to yet another Chinese drugmaker after finding it had been hiding batch tests results that showed high peaks of out-of-spec…

Company says it is planning to launch a 'sizeable' vaccines portfolio starting in 2018.

Starting this week, we’ll be changing the frequency of <em>FiercePharmaAsia</em> to a once-weekly report. Moving forward, you will receive your…

Another Indian API maker is in trouble over manufacturing issues. This time it is an Artemis Biotech plant in Hyderabad and it is the German drug authority…